Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on QURE stock, giving a Buy rating on August 14.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Schwartz has given his Buy rating due to a combination of factors surrounding uniQure’s upcoming data release for AMT-130 in Huntington’s disease. The data, expected in September 2025, is crucial for supporting their Biologics License Application submission in early 2026. Schwartz highlights the company’s strategic alignment with the FDA for accelerated approval, which has been a significant factor in the stock’s volatility.
Schwartz believes that the forthcoming data could provide strong evidence for accelerated approval, particularly if it shows statistically significant slowing of disease progression compared to a control group. This potential positive outcome could shift investor focus towards a commercial launch, despite the complexities involved in the treatment procedure. Consequently, Schwartz sees substantial upside potential for uniQure’s stock, maintaining it as a top pick with a price target of $48.
In another report released on August 14, Mizuho Securities also upgraded the stock to a Buy with a $30.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.